Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.
Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine.
复制标题
DOI：
10.1002/cpt.134
复制
发表时间：
2015-07
影响因子：
6.7
通讯作者：
Pharmacometabolomics Research Network
中科院分区：
文献类型：
--
作者：
Kaddurah-Daouk R;Weinshilboum R;Pharmacometabolomics Research Network
随着临床药理学数据量的增加以及系统生物学和药理学的融合，出现了一门新的学科--定量与系统药理学（QSP）。这一新的研究方向可能会大大促进治疗药物的发现、开发和临床应用。来自计算生物学、系统生物学和生物工程的研究团体与药理学家、遗传学家、生物化学家和分析化学家合作，正在创建和建模关于药物效应的大数据，这些数据正在改变我们对这些药物如何在网络层面上发挥作用的理解。在这篇综述中，我们强调了一个新的和快速增长的领域-药物代谢组学的发展-其中大的生物化学数据捕获基因组，肠道微生物组和环境暴露的影响揭示了有关代谢型和治疗结果的信息，并创建代谢特征作为新的潜在生物标志物。药物代谢组学为药物基因组学提供了信息和补充，它们共同为QSP提供了基石。
The scaling up of data in clinical pharmacology and the merger of systems biology and pharmacology has led to the emergence of a new discipline of Quantitative and Systems Pharmacology (QSP). This new research direction might significantly advance the discovery, development and clinical use of therapeutic drugs. Research communities from computational biology, systems biology and biological engineering—working collaboratively with pharmacologists, geneticists, biochemists and analytical chemists—are creating and modeling large data on drug effects that is transforming our understanding of how these drugs work at a network level. In this review, we highlight developments in a new and rapidly growing field—pharmacometabolomics—in which large biochemical data-capturing effects of genome, gut microbiome and environment exposures is revealing information about metabotypes and treatment outcomes, and creating metabolic signatures as new potential biomarkers. Pharmacometabolomics informs and compliments pharmacogenomics and together they provide building blocks for QSP.